Cagrilintide

7 trials

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

0 Recruiting

6 Completed trials

1 Sponsors

21 Countries

Phase III

Phase II

Phase III/IV

Phase III: 3 Phase II: 3 Phase III/IV: 1

Oversight events:

3 serious breaches across 2 trials

View oversight register →

Indications tested

Alcoholic liver disease 1 Overweight 1 Obesity 1 Chronic kidney disease 1

Sponsors using this IMP

Novo Nordisk A/S 7

All trials

7 total

A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending

2023-509176-42-00 Phase III/IV 14 countries Novo Nordisk A/S
Weight loss in people living with overweight or obesity following treatment with cagrilintide Ended

2024-519530-24-00 Phase III 5 countries Novo Nordisk A/S
Weight loss in people living with overweight or obesity and type 2 diabetes following treatment with cagrilintide Ended

2024-519531-41-00 Phase III 5 countries Novo Nordisk A/S
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat… Ended

2023-508170-28-00 Phase II 10 countries Novo Nordisk A/S
A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended

2023-505857-42-00 Phase II 6 countries Novo Nordisk A/S
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended

2022-502678-18-00 Phase III 15 countries Novo Nordisk A/S
Research study on whether a combination of 2 medicines (NNC0194-0499 and Semaglutide) works in people with non-alcoholic steatohepatitis (NA… Ended

2023-506961-74-00 Phase II 11 countries Novo Nordisk A/S

Showing 1–7 of 7 trials

← All drugs A–Z